Mnemo Therapeutics
Justin Eyquem, PhD, is Scientific Co-Founder and Scientific Advisor at Mnemo. Justin has extensive research experience in cancer immunotherapy, with research interests including genome editing, CAR T cell immunology, and developing novel CAR designs that recognize low tumor antigen density. He previously worked in Michel Sadelain’s lab at MSKCC to engineer CAR T cells using CRISPR/Cas9. In 2019, Justin was honored with the Parker Fellow Award and opened the Eyquem Lab in the department of Microbiology and Immunology at the University of California, San Francisco. At his lab, he is developing a gene editing platform to enhance CAR T and NK cell functions in hematological and solid tumors. Justin earned his PhD from the University of Paris-Diderot in collaboration with the biotech company Cellectis.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.